Background: The objective of this study is to assess the clinical manifestations and prognostic value of age on overall survival (OS) and cancer-specific survival (CSS) for hypopharynx squamous cell carcinoma (SCC) using the Surveillance, Epidemiology and End Results (SEER) database.
Methods: Patients with hypopharynx SCC were extracted from the SEER database between 2004 and 2014. We examined the clinicopathological variables using Chi-squared tests and we evaluated the association between survival and different variables, including age, race, grade, tumour location, T category, N category and surgery therapies to the primary tumour, using the methods of Kaplan-Meier. Univariate and multivariate analyses were performed to determine the effects of each variable on survival.
Results: A total of 3702 patients were analysed. The patients aged 25-49 tended to be black and present withN3 and stage IV (P <.01). In multivariate analyses, the patients aged 25-39 had better survival rates, and the risk of death became higher with increasing age. Compared with patients aged 25 to 39 years, the hazard ratios for patients aged 40-49, 50-59, 60-69, 70-79 and 80-95 years were 1.190 (95% confidence interval [CI] 0.584-2.423), 1.156 (95% CI 0.575-2.324), 1.315 (95% CI 0.654-2.642), 1.780 (95% CI 0.884-3.584) and 2.614 (95% CI 1.292-5.288) respectively. Subgroups analysis shows that the effect of advancing age was significantly associated with a higher risk of poor survival in patients who harboured moderately/poorly differentiated (all P <.05), T1-T4a, N0-N2b or stage I-IVa disease (all P <.05, respectively).
Conclusion: Younger patients tended to present with advanced N classification. Increasing age at diagnosis was associated with a significantly higher risk of poorer OS. However, when considering patients affected by more aggressive disease, age was not significantly associated with higher risk of dying from hypopharynx SCC. In high-risk patients, tumour characteristics rather than age should be considered when making treatment decisions.
© 2021 John Wiley & Sons Ltd.